- Details
- At the 2024 UCSF-UCLA PSMA Conference, Carlos Uribe emphasizes the critical role of dosimetry in enhancing the precision and personalization of radiopharmaceutical therapies (RPTs), detailing how it quantifies radiation doses to tumors and healthy tissues to optimize treatment outcomes. Dr. Uribe addresses challenges in dosimetry implementation and proposes innovative solutions, including the deve...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Matthew Rettig discusses the critical advancements and challenges in treating metastatic castration-resistant prostate cancer (mCRPC), highlighting the shift towards precision oncology with FDA-approved treatments like PARP inhibitors and Lutetium PSMA therapy, tailored to genetic mutations and PSMA PET imaging findings. Dr. Rettig emphasizes the importance o...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett explores the interaction between PSMA and androgen receptors in prostate cancer, focusing on their role across different disease states and the impact on treatment and imaging. Dr. Emmett highlights the ENZA-P trial, a study investigating the combination of Enzalutamide with Lutetium PSMA in metastatic castrate-resistant prostate cancer, emphasi...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett emphasizes the importance of SPECT imaging in assessing early and interim responses to Lutetium PSMA therapy in prostate cancer, challenging the adequacy of traditional biomarkers like PSA and RECIST. Dr. Emmett discusses a nuanced approach to treatment personalization, suggesting that integrating SPECT imaging with other biomarkers could enhanc...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Oliver Sartor advocates for the early use of PSMA radioligand therapy in prostate cancer treatment, challenging the traditional reliance on castration and chemotherapy due to their significant side effects. Dr. Sartor urges a shift in evaluating therapy efficacy, focusing on patient preference and practical decision-making in clinical settings, and calls for...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Jeremie Calais highlights the advanced diagnostic capabilities of PSMA PET/SPECT in monitoring responses to PSMA-targeted radiopharmaceutical therapy, showcasing its superiority over traditional CT and bone scans through patient cases. Dr. Calais discusses the importance of nuanced evaluation methods, including PPP and RECIP criteria, alongside PSA levels and...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Amar Kishan highlights the significant impact of PSMA PET imaging on clinical trials for localized prostate cancer, particularly its role in refining intermediate clinical endpoints like metastasis-free survival. Dr. Kishan discusses the potential of PSMA PET to alter trial outcomes by early detection of distant metastases, referencing trials like STARPORT, I...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler emphasizes the transformative role of PSMA-PET imaging in managing castration-resistant prostate cancer (CRPC), showcasing its ability to reveal a more extensive disease burden and detect distant metastases in patients previously considered non-metastatic. Dr. Fendler highlights a multicenter trial that demonstrates PSMA-PET's significant imp...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Jeremie Calais discusses the critical role of PSMA PET in selecting patients for PSMA radiopharmaceutical therapy, using the VISION trial criteria to highlight the importance of precise patient selection based on PSMA PET imaging for predicting treatment effectiveness and side effects. Dr. Calais explores the comparability of different PSMA ligands and the po...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Thomas Hope, Michael Morris, and Oliver Sartor discuss the nuances of three trials—PSMAfore, SPLASH, and ECLIPSE—in the pre-chemotherapy metastatic CRPC setting, focusing on the ambition to advance Lutetium PSMA therapy earlier in treatment. They explore differences in trial designs, patient selection, and outcomes, with Dr. Morris detailing PSMAfore's succes...
|
